Core Viewpoint - The company is focusing on the commercialization of synthetic biology products, which are currently in a ramp-up phase of production, with improved order conditions compared to the previous year [1] Group 1: Synthetic Biology Products - The synthetic biology products currently in mass production include resveratrol, 5-hydroxytryptophan, ergothioneine, squalene, and inositol [1] - As of the third quarter of 2025, the revenue from synthetic biology products is projected to be 44.8 million yuan [1] - The company adheres to a dual-driven strategy of "biological fermentation + synthetic biology" to continuously optimize production processes [1] Group 2: Production Capacity and Orders - The synthetic biology base is still in the capacity ramp-up phase [1] - There has been an improvement in order conditions compared to the same period last year [1] - The company is actively promoting the commercialization process of synthetic biology products [1]

Core Viewpoint - The company is focusing on the commercialization of synthetic biology products, with a dual strategy of "biological fermentation + synthetic biology" to optimize production processes and improve order conditions compared to the previous year [1] Group 1: Synthetic Biology Products - Current mass-produced synthetic biology products include red yeast rice, 5-hydroxytryptophan, ergothioneine, squalene, and inositol [1] - By the third quarter of 2025, the revenue from synthetic biology products is projected to reach 44.8 million yuan [1] Group 2: Production Capacity and Strategy - The synthetic biology base is still in the capacity ramp-up phase this year [1] - The company is committed to continuously optimizing production processes and actively promoting the commercialization of synthetic biology products [1]

Investment Rating - The report does not explicitly state an investment rating for the eczema ointment market in China Core Insights - The Chinese eczema ointment market is characterized by a growing demand for innovative solutions that balance efficacy and safety, driven by a trend of patient consumerization and the prevalence of unsafe products containing illegal hormone additives [5][7] - The report emphasizes that only products with the "National Drug Approval Number" can ensure safety and efficacy, highlighting the innovative non-hormonal drug, Zeli Mei® (Benvimod Cream), as a representative of future market direction [5][10] Summary by Sections Market Overview - Eczema is a chronic, recurrent inflammatory skin disease affecting 15% to 30% of dermatology patients, with topical medications accounting for 67% of treatment options [15][25] - Non-hormonal topical agents are crucial due to the potential adverse effects of long-term steroid use, with Benvimod Cream showing significant clinical advantages in efficacy and safety [15][21] Product Categories and Efficacy Analysis - The report outlines the importance of recognizing "National Drug Approval Number" products as the only legally validated treatment for eczema, with a focus on innovative drugs that enhance both efficacy and safety [10][42] - The market is transitioning from traditional to innovative drugs, with a notable increase in online pharmacy sales, reaching 1.78 billion yuan in Q2 2025, a year-on-year growth of over 37% [35][42] Patient Behavior and Awareness - The primary demographics of eczema patients in China are children (ages 2-12) and young adults (ages 18-60), with nearly 90% of cases being mild to moderate [48][54] - Patients prioritize ingredient safety and brand reputation when purchasing topical medications, with over 40% avoiding steroid treatments due to concerns about side effects [48][60] - The digital healthcare landscape is evolving, with e-commerce becoming a significant growth driver for dermatological products, as online medical consultations are increasingly popular [61][62] Market Issues and Analysis - The report identifies significant market issues, including the prevalence of misleading advertising and unsafe products, which pose serious health risks to consumers, particularly infants [9][10] - It stresses the need for strict regulatory measures to eliminate non-compliant products and promote a market focused on innovative, compliant drugs [10][42]

Core Viewpoint - The article highlights the transformative potential of synthetic biology in traditional industries, particularly in agriculture, through a strategic partnership between GELEXIMCO Group, Vietnam National University of Agriculture, and Senrise Biotechnology [1][10]. Group 1: Market Overview - The global synthetic biology market is projected to reach $16 billion by 2024, with an annual growth rate of 27% over the past five years [1]. - Vietnam's agricultural market is substantial, with an estimated total output value of around $50 billion in 2024, showing a rising demand for green agricultural bioproducts [4]. Group 2: Strategic Partnership - The collaboration aims to develop and mass-produce synthetic biological products such as ginsenoside, jasmonate, and astaxanthin, focusing on sustainable agricultural practices [1][4]. - This partnership is expected to enhance cooperation between China and Vietnam in cutting-edge biotechnology, injecting new momentum into the green transformation of agriculture in ASEAN [1][10]. Group 3: Company Profiles - GELEXIMCO Group is a significant player in Vietnam's economy, with annual revenues exceeding 200 trillion VND and total assets reaching 800 trillion VND, aiming to establish a competitive synthetic biology platform [6]. - Vietnam National University of Agriculture is a leading institution in agricultural education and research, providing expertise and local insights for the partnership [7]. - Senrise Biotechnology has developed over 70 patents and utilizes AI algorithms and automated platforms for efficient production, focusing on high-yield chassis cells and precision fermentation [8]. Group 4: Societal Impact - The collaboration is expected to significantly contribute to Vietnam's agricultural green transformation and high-quality development by promoting environmentally friendly agricultural practices [10]. - The project will foster talent development in synthetic biology and modern agriculture, establishing a collaborative innovation platform between academia and industry [10].